CRISPR Therapeutics AG(CRSP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CRSP CRISPR Therapeutics AG

盘前交易 05-08 07:01:48 EDT

55.53

-1.53

-2.68%

盘前55.53

+0.000.00%

06:37 EDT

最高57.10	最低55.27	成交量137.72万
今开57.00	昨收57.06	日振幅3.21%
总市值47.14亿	流通市值46.30亿	总股本8,488万
成交额7,718万	换手率1.65%	流通股本8,337万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"CRSP","market":"US","secType":"STK","nameCN":"CRISPR Therapeutics AG","latestPrice":55.53,"timestamp":1715112000000,"preClose":57.06,"halted":0,"volume":1377179,"hourTrading":{"tag":"盘前","latestPrice":55.53,"preClose":55.53,"latestTime":"06:37 EDT","volume":32,"amount":1787.64,"timestamp":1715164675250},"delay":0,"floatShares":83369905,"shares":84883091,"eps":-1.939999,"marketStatus":"盘前交易","marketStatusCode":1,"change":-1.53,"latestTime":"05-08 07:01:48 EDT","open":57,"high":57.1,"low":55.27,"amount":77182165.40693,"amplitude":0.032072,"askPrice":56.5,"askSize":2,"bidPrice":55.5,"bidSize":4,"shortable":3,"etf":0,"ttmEps":-1.939999,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715175000000},"adr":0,"listingDate":1476849600000,"adjPreClose":55.53,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":55.53,"preClose":55.53,"latestTime":"06:37 EDT","volume":32,"amount":1787.64,"timestamp":1715164675250},"postHourTrading":{"tag":"盘后","latestPrice":55.59,"preClose":55.53,"latestTime":"19:57 EDT","volume":15986,"amount":888818.6178,"timestamp":1715126248344},"volumeRatio":1.084777900103945},"requestUrl":"/m/hq/s/CRSP/tweets","defaultTab":"tweets","newsList":[{"id":"2432706659","title":"Crispr Therapeutics Ag盘中异动 早盘大幅上涨5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432706659","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432706659?lang=zh_cn&edition=full","pubTime":"2024-05-03 21:31","pubTimestamp":1714743060,"startTime":"0","endTime":"0","summary":"北京时间2024年05月03日21时31分，Crispr Therapeutics Ag股票出现波动，股价快速拉升5.27%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体涨幅为0.06%。Crispr Therapeutics Ag公司简介：Crispr Therapeutics 是一家基因编辑公司，专注于开发基于 CRISPR/Cas9 的疗法。Crispr 的第一个获批药物是 Casgevy，该药物是与 Vertex Pharmaceuticals 合作开发的，针对镰状细胞病和输血依赖性β地中海贫血，这些疾病的医疗需求尚未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405032131007a57fb05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405032131007a57fb05&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432357526","title":"Crispr Therapeutics Ag盘中异动 快速上涨5.00%报55.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432357526","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432357526?lang=zh_cn&edition=full","pubTime":"2024-05-02 02:58","pubTimestamp":1714589915,"startTime":"0","endTime":"0","summary":"北京时间2024年05月02日02时58分，Crispr Therapeutics Ag股票出现异动，股价快速上涨5.00%。截至发稿，该股报55.64美元/股，成交量78.0638万股，换手率0.92%，振幅5.36%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体涨幅为2.21%。Crispr Therapeutics Ag公司简介：Crispr Therapeutics 是一家基因编辑公司，专注于开发基于 CRISPR/Cas9 的疗法。Crispr 的第一个获批药物是 Casgevy，该药物是与 Vertex Pharmaceuticals 合作开发的，针对镰状细胞病和输血依赖性β地中海贫血，这些疾病的医疗需求尚未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405020258357925a4f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405020258357925a4f3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431394750","title":"又一张百亿牌桌要翻？","url":"https://stock-news.laohu8.com/highlight/detail?id=2431394750","media":"陈广晶","top":-1,"share":"https://www.laohu8.com/m/news/2431394750?lang=zh_cn&edition=full","pubTime":"2024-04-30 17:24","pubTimestamp":1714469052,"startTime":"0","endTime":"0","summary":"人类科学家再遭降维打击。","market":"us","thumbnail":"https://img.huxiucdn.com/article/cover/202404/30/130915927869.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg","type":0,"news_type":0,"thumbnails":["https://img.huxiucdn.com/article/cover/202404/30/130915927869.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.huxiu.com/article/2971322.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429554486","title":"AI能够重写人类基因组了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2429554486","media":"新智元","top":-1,"share":"https://www.laohu8.com/m/news/2429554486?lang=zh_cn&edition=full","pubTime":"2024-04-24 16:03","pubTimestamp":1713945799,"startTime":"0","endTime":"0","summary":"全球首个基因编辑器开源了","market":"sg","thumbnail":"https://img.huxiucdn.com/article/cover/202404/24/134147933434.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg","type":0,"news_type":0,"thumbnails":["https://img.huxiucdn.com/article/cover/202404/24/134147933434.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.huxiu.com/article/2946337.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429113661","title":"Crispr Therapeutics Ag盘中异动 早盘急速拉升5.03%报58.46美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429113661","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429113661?lang=zh_cn&edition=full","pubTime":"2024-04-23 22:02","pubTimestamp":1713880938,"startTime":"0","endTime":"0","summary":"北京时间2024年04月23日22时02分，Crispr Therapeutics Ag股票出现波动，股价大幅拉升5.03%。截至发稿，该股报58.46美元/股，成交量13.5611万股，换手率0.16%，振幅4.74%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体涨幅为1.43%。Crispr Therapeutics Ag公司简介：Crispr Therapeutics 是一家基因编辑公司，专注于开发基于 CRISPR/Cas9 的疗法。Crispr 的第一个获批药物是 Casgevy，该药物是与 Vertex Pharmaceuticals 合作开发的，针对镰状细胞病和输血依赖性β地中海贫血，这些疾病的医疗需求尚未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240423220219861e82ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240423220219861e82ed&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427709355","title":"或比CRISPR更安全更灵活，RNA编辑疗法加速发展-36氪","url":"https://stock-news.laohu8.com/highlight/detail?id=2427709355","media":"科技日报","top":-1,"share":"https://www.laohu8.com/m/news/2427709355?lang=zh_cn&edition=full","pubTime":"2024-04-15 08:12","pubTimestamp":1713139956,"startTime":"0","endTime":"0","summary":"据英国《自然》杂志网站近日报道，目前至少有3种RNA编辑疗法正在获批或已进入临床试验。支持者认为，该技术可能比CRISPR等基因组编辑技术更安全更灵活。与CRISPR基因组编辑不同，RNA编辑不会改变基因，也不会产生永久性的变化。美国伍兹霍尔海洋研究所生物实验室神经生物学家约书亚·罗森泰指出，这种短暂性可能会带来安全优势。因为能“剪切”DNA的CRISPR疗法的一个风险是脱靶效应，如果是RNA内出现脱靶效应，危险要小得多。（科技日报）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415081241877ca281&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415081241877ca281&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426681492","title":"Crispr Therapeutics Ag盘中异动 早盘大幅跳水5.05%报61.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426681492","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426681492?lang=zh_cn&edition=full","pubTime":"2024-04-10 21:35","pubTimestamp":1712756108,"startTime":"0","endTime":"0","summary":"北京时间2024年04月10日21时35分，Crispr Therapeutics Ag股票出现异动，股价快速下跌5.05%。截至发稿，该股报61.90美元/股，成交量10.4069万股，换手率0.12%，振幅1.35%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体跌幅为1.10%。Crispr Therapeutics Ag公司简介：CRISPR Therapeutics 是一家基因编辑公司，专注于开发基于 CRISPR/Cas9 的疗法。CRISPR/Cas9 全称 Clustered Regularly Interspaced Short Palindromic Repeats /CRISPR-associated protein 9 ，这是一项精确改变基因组 DNA 特定序列的革命性技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404102135097a51e80d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404102135097a51e80d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420663107","title":"荷兰研究人员：用CRISPR基因编辑疗法在实验室环境下“消灭”艾滋病毒","url":"https://stock-news.laohu8.com/highlight/detail?id=2420663107","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2420663107?lang=zh_cn&edition=full","pubTime":"2024-03-20 12:53","pubTimestamp":1710910435,"startTime":"0","endTime":"0","summary":"2024年3月19日，荷兰阿姆斯特丹大学的研究人员在一次医学会议上介绍称，他们利用获得CRISPR基因编辑技术，成功地从受感染细胞中消除了艾滋病毒。“分子剪刀”定向灭活HIV在此次医学会议上，荷兰阿姆斯特丹大学的研究人员提前发表了一项新研究，展示了如何使用最新的CRISPR-Cas基因编辑技术消除实验室环境下受感染细胞中的所有艾滋病病毒痕迹。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"fenghuang_stock","url":"https://tech.ifeng.com/c/8Y6VybG4PjO","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8Y6VybG4PjO","is_publish_highlight":false,"gpt_icon":0},{"id":"2419986569","title":"Intellia Therapeutics, Inc.盘中异动 股价大跌5.20%报27.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419986569","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419986569?lang=zh_cn&edition=full","pubTime":"2024-03-14 23:09","pubTimestamp":1710428998,"startTime":"0","endTime":"0","summary":"北京时间2024年03月14日23时09分，Intellia Therapeutics, Inc.股票出现异动，股价大幅跳水5.20%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.61%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031423095887e78f8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031423095887e78f8f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417425933","title":"Intellia Therapeutics, Inc.盘中异动 股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417425933","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417425933?lang=zh_cn&edition=full","pubTime":"2024-03-06 03:10","pubTimestamp":1709665831,"startTime":"0","endTime":"0","summary":"北京时间2024年03月06日03时10分，Intellia Therapeutics, Inc.股票出现波动，股价快速跳水5.00%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.48%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030603103179178cc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030603103179178cc2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416600642","title":"Intellia Therapeutics, Inc.盘中异动 股价大涨5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416600642","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416600642?lang=zh_cn&edition=full","pubTime":"2024-03-01 23:21","pubTimestamp":1709306485,"startTime":"0","endTime":"0","summary":"北京时间2024年03月01日23时21分，Intellia Therapeutics, Inc.股票出现异动，股价快速上涨5.20%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.76%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403012321257a48980e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403012321257a48980e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416669571","title":"Crispr Therapeutics Ag盘中异动 大幅跳水5.03%报83.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2416669571","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416669571?lang=zh_cn&edition=full","pubTime":"2024-03-01 01:52","pubTimestamp":1709229174,"startTime":"0","endTime":"0","summary":"北京时间2024年03月01日01时52分，Crispr Therapeutics Ag股票出现异动，股价快速下跌5.03%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体跌幅为1.31%。Crispr Therapeutics Ag公司简介：CRISPR Therapeutics 是一家基因编辑公司，专注于开发基于 CRISPR/Cas9 的疗法。CRISPR/Cas9 全称 Clustered Regularly Interspaced Short Palindromic Repeats /CRISPR-associated protein 9 ，这是一项精确改变基因组 DNA 特定序列的革命性技术。CRISPR 最先进的管道候选药物 exa-cel 与 Vertex Pharmaceuticals 合作，针对镰状细胞病和输血依赖性β-地中海贫血，这些疾病的医疗需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240301015254861da3c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240301015254861da3c9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2415552941","title":"Intellia Therapeutics, Inc.盘中异动 早盘快速上涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2415552941","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2415552941?lang=zh_cn&edition=full","pubTime":"2024-02-29 22:48","pubTimestamp":1709218089,"startTime":"0","endTime":"0","summary":"北京时间2024年02月29日22时48分，Intellia Therapeutics, Inc.股票出现异动，股价大幅上涨5.00%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.17%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022922480987e74e76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022922480987e74e76&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2414801110","title":"Editas Medicine Inc盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2414801110","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2414801110?lang=zh_cn&edition=full","pubTime":"2024-02-27 23:34","pubTimestamp":1709048067,"startTime":"0","endTime":"0","summary":"北京时间2024年02月27日23时34分，Editas Medicine Inc股票出现波动，股价大幅拉升5.02%。截至发稿，该股报8.47美元/股，成交量44.7161万股，换手率0.55%，振幅4.34%。Editas Medicine Inc股票所在的生物技术行业中，整体跌幅为0.42%。其相关个股中，Janux Therapeutics Inc、Viking Therapeutics Inc、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Scisparc Ltd、Zyversa Therapeutics Inc、Galera Therapeutics Inc较为活跃，换手率分别为345.61%、159.64%、34.38%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Janux Therapeutics Inc、Viking Therapeutics Inc，振幅分别为87.23%、70.86%、50.96%。Editas Medicine Inc公司简介：Editas Medicine Inc 是一家基因组编辑公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240227233427861d8e2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240227233427861d8e2d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2414781505","title":"首批 CRISPR 基因编辑后的猪肉等待评估，未来两年有望送上餐桌","url":"https://stock-news.laohu8.com/highlight/detail?id=2414781505","media":"IT之家","top":-1,"share":"https://www.laohu8.com/m/news/2414781505?lang=zh_cn&edition=full","pubTime":"2024-02-27 11:56","pubTimestamp":1709006187,"startTime":"0","endTime":"0","summary":"IT之家 2 月 27 日消息，根据国外科技媒体 New Scientist 报道，在可以预见的未来，经过基因编辑改造的猪肉将进入超市货架，成为普通人日常餐桌上的食物。名为 Genus 正准备将一批经过基因编辑的猪推向市场，这些猪经过改造后对疾病具有免疫力。如果该项目获得批准，预估最快 2 年内我们就能在商店货架上看到转基因猪肉。...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/Oj0OKEMV0ZB0Jn-5KltSh2USyXzfB3QfVhZnpgPgo2Ma4AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/Oj0OKEMV0ZB0Jn-5KltSh2USyXzfB3QfVhZnpgPgo2Ma4AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240227A03DP100","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240227A03DP100","is_publish_highlight":false,"gpt_icon":0},{"id":"2413209657","title":"强脑科技创始人韩璧丞：美国很多关键技术其实都是华人做出来的","url":"https://stock-news.laohu8.com/highlight/detail?id=2413209657","media":"睿见Economy","top":-1,"share":"https://www.laohu8.com/m/news/2413209657?lang=zh_cn&edition=full","pubTime":"2024-02-23 10:15","pubTimestamp":1708654500,"startTime":"0","endTime":"0","summary":"　　2024年亚布力中国企业家论坛第24届年会于2月21日-23日举行。强脑科技创始人、CEO韩璧丞出席数字经论坛并分享了自己的观点。　　韩璧丞认为，美国很多关键的技术，其实都是华人做出来的，“比如说这个基因编辑CRISPR-Cas9，其实都是张锋、杨璐菡，还有丛乐这些教授做的，包括现在你看很多这个AI的这个核心团队里面，也有大量的华人，我当时其实印象比较深刻。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/hy/hyjz/2024-02-23/doc-inaiyvxu5022451.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2024-02-23/doc-inaiyvxu5022451.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2413427483","title":"BUZZ-CRISPR Therapeutics 因季度利润向好而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2413427483","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413427483?lang=zh_cn&edition=full","pubTime":"2024-02-21 23:34","pubTimestamp":1708529677,"startTime":"0","endTime":"0","summary":" (更新)    2月21日 - ** 瑞士基因编辑公司CRISPR Therapeutics在美国上市的股票  上涨2.6%，报80.8美元。** 第四季度营收为 2.012 亿美元，预计为1.316 亿美元 - LSEG** CRISPR和VertexPharmaceuticals公司的  基因疗法Casgevy 预计将于今年年初在美国 上市，用于治疗两种不同的、已获批准的遗传性血液疾病。** 券商TD Cowen预计， Casgevy在整个2024年的销售额将远低于共识，称主要 意见领袖预计 ，由于各种限制，商业化将是一个挑战。** 截至上次收盘，该公司在美国上市的股票在过去12个月中上涨了54.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413422565","title":"Crispr Therapeutics Ag盘中异动 股价大涨5.42%报83.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413422565","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413422565?lang=zh_cn&edition=full","pubTime":"2024-02-21 22:31","pubTimestamp":1708525910,"startTime":"0","endTime":"0","summary":"北京时间2024年02月21日22时31分，Crispr Therapeutics Ag股票出现异动，股价快速上涨5.42%。截至发稿，该股报83.00美元/股，成交量27.6019万股，换手率0.33%，振幅2.13%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体跌幅为0.32%。Crispr Therapeutics Ag公司简介：CRISPR Therapeutics 是一家基因编辑公司，专注于开发基于 CRISPR/Cas9 的疗法。CRISPR/Cas9 全称 Clustered Regularly Interspaced Short Palindromic Repeats /CRISPR-associated protein 9 ，这是一项精确改变基因组 DNA 特定序列的革命性技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402212231507a455e2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402212231507a455e2d&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.crisprtx.com","stockEarnings":[{"period":"1week","weight":0.0479},{"period":"1month","weight":-0.1172},{"period":"3month","weight":-0.1551},{"period":"6month","weight":0.0833},{"period":"1year","weight":-0.0077},{"period":"ytd","weight":-0.1129}],"compareEarnings":[{"period":"1week","weight":0.0302},{"period":"1month","weight":-0.0025},{"period":"3month","weight":0.0382},{"period":"6month","weight":0.192},{"period":"1year","weight":0.2529},{"period":"ytd","weight":0.088}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"CRISPR Therapeutics AG作为一家瑞士股份公司在Inception Genomics AG名下于2013年10月31日注册成立。他们是一家领先的基因研究的公司，专注于CRISPR/Cas9的疗法发展。 CRISPR/ Cas9代表集群，定期相互间隔短回文重复（CRISPR）相关蛋白9，是改变基因的编排，基因组DNA的特定序列过程中的一项革命性的技术。他们正在应用此技术通过破坏，纠正或调节与疾病相关的基因来治疗广泛的稀有或常见的疾病。他们最先进的项目是针对β-地中海贫血和镰状细胞病，这种病症的治疗需要两个满足高医疗需求的血红蛋白。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.090159},{"month":2,"riseRate":0.625,"avgChangeRate":0.089566},{"month":3,"riseRate":0.25,"avgChangeRate":-0.077241},{"month":4,"riseRate":0.625,"avgChangeRate":-0.022564},{"month":5,"riseRate":0.625,"avgChangeRate":0.111885},{"month":6,"riseRate":0.714286,"avgChangeRate":0.112056},{"month":7,"riseRate":0.714286,"avgChangeRate":0.020889},{"month":8,"riseRate":0.571429,"avgChangeRate":0.019414},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.107923},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.054271},{"month":11,"riseRate":0.75,"avgChangeRate":0.223716},{"month":12,"riseRate":0.25,"avgChangeRate":-0.050604}],"exchange":"NASDAQ","name":"CRISPR Therapeutics AG","nameEN":"CRISPR Therapeutics AG"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CRISPR Therapeutics AG(CRSP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供CRISPR Therapeutics AG(CRSP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"CRISPR Therapeutics AG,CRSP,CRISPR Therapeutics AG股票,CRISPR Therapeutics AG股票老虎,CRISPR Therapeutics AG股票老虎国际,CRISPR Therapeutics AG行情,CRISPR Therapeutics AG股票行情,CRISPR Therapeutics AG股价,CRISPR Therapeutics AG股市,CRISPR Therapeutics AG股票价格,CRISPR Therapeutics AG股票交易,CRISPR Therapeutics AG股票购买,CRISPR Therapeutics AG股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CRISPR Therapeutics AG(CRSP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供CRISPR Therapeutics AG(CRSP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}